hVIVO’s (HVO) “Buy” Rating Reiterated at Peel Hunt

hVIVO (LON:HVO)‘s stock had its “buy” rating reaffirmed by stock analysts at Peel Hunt in a note issued to investors on Monday, Digital Look reports. They presently have a GBX 14 price target on the stock. Peel Hunt’s target price suggests a potential upside of 139.73% from the company’s current price.

hVIVO Price Performance

Shares of LON HVO opened at GBX 5.84 on Monday. The stock has a market cap of £40.20 million, a price-to-earnings ratio of -3.28 and a beta of 1.69. The company has a debt-to-equity ratio of 43.38, a quick ratio of 1.16 and a current ratio of 1.21. hVIVO has a fifty-two week low of GBX 4.30 and a fifty-two week high of GBX 11. The firm’s 50-day simple moving average is GBX 6.42 and its 200 day simple moving average is GBX 7.15.

hVIVO (LON:HVO) last released its quarterly earnings results on Tuesday, September 15th. The company reported GBX (0.82) earnings per share (EPS) for the quarter. hVIVO had a negative net margin of 31.76% and a negative return on equity of 35.13%. As a group, research analysts anticipate that hVIVO will post 1.55 earnings per share for the current fiscal year.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.